CN102393373A - 一种消除内源性胱硫醚干扰的血清同型半胱氨酸测定方法及试剂 - Google Patents
一种消除内源性胱硫醚干扰的血清同型半胱氨酸测定方法及试剂 Download PDFInfo
- Publication number
- CN102393373A CN102393373A CN2011103401359A CN201110340135A CN102393373A CN 102393373 A CN102393373 A CN 102393373A CN 2011103401359 A CN2011103401359 A CN 2011103401359A CN 201110340135 A CN201110340135 A CN 201110340135A CN 102393373 A CN102393373 A CN 102393373A
- Authority
- CN
- China
- Prior art keywords
- concentration
- reagent
- homocysteine
- hcy
- cystathionie
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- FFFHZYDWPBMWHY-VKHMYHEASA-N L-homocysteine Chemical compound OC(=O)[C@@H](N)CCS FFFHZYDWPBMWHY-VKHMYHEASA-N 0.000 title claims abstract description 122
- 239000003153 chemical reaction reagent Substances 0.000 title claims abstract description 71
- 210000002966 serum Anatomy 0.000 title claims abstract description 47
- YPWSLBHSMIKTPR-UHFFFAOYSA-N Cystathionine Natural products OC(=O)C(N)CCSSCC(N)C(O)=O YPWSLBHSMIKTPR-UHFFFAOYSA-N 0.000 title claims abstract description 17
- ILRYLPWNYFXEMH-UHFFFAOYSA-N D-cystathionine Natural products OC(=O)C(N)CCSCC(N)C(O)=O ILRYLPWNYFXEMH-UHFFFAOYSA-N 0.000 title claims abstract description 17
- 238000000034 method Methods 0.000 title abstract description 22
- ILRYLPWNYFXEMH-WHFBIAKZSA-N L-cystathionine Chemical compound [O-]C(=O)[C@@H]([NH3+])CCSC[C@H]([NH3+])C([O-])=O ILRYLPWNYFXEMH-WHFBIAKZSA-N 0.000 title abstract 4
- 101710088194 Dehydrogenase Proteins 0.000 claims abstract description 16
- 238000002835 absorbance Methods 0.000 claims description 31
- BAWFJGJZGIEFAR-NNYOXOHSSA-N NAD zwitterion Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-N 0.000 claims description 21
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims description 20
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims description 20
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims description 20
- 238000006243 chemical reaction Methods 0.000 claims description 19
- 229950006238 nadide Drugs 0.000 claims description 18
- 108090000856 Lyases Proteins 0.000 claims description 15
- 102000004317 Lyases Human genes 0.000 claims description 15
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 claims description 15
- BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 claims description 15
- 238000001514 detection method Methods 0.000 claims description 14
- 239000000463 material Substances 0.000 claims description 14
- 108010073644 Cystathionine beta-synthase Proteins 0.000 claims description 13
- 238000013016 damping Methods 0.000 claims description 12
- 239000012530 fluid Substances 0.000 claims description 12
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 11
- 230000002452 interceptive effect Effects 0.000 claims description 10
- 238000012360 testing method Methods 0.000 claims description 9
- 239000008367 deionised water Substances 0.000 claims description 7
- 229910021641 deionized water Inorganic materials 0.000 claims description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 7
- 238000012544 monitoring process Methods 0.000 claims description 4
- 230000009467 reduction Effects 0.000 claims description 4
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims description 3
- 239000011259 mixed solution Substances 0.000 claims description 3
- 230000008878 coupling Effects 0.000 abstract description 3
- 238000010168 coupling process Methods 0.000 abstract description 3
- 238000005859 coupling reaction Methods 0.000 abstract description 3
- 238000005259 measurement Methods 0.000 abstract description 3
- 238000010339 medical test Methods 0.000 abstract description 2
- 239000000126 substance Substances 0.000 abstract 1
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 14
- 238000002360 preparation method Methods 0.000 description 8
- 230000000694 effects Effects 0.000 description 7
- 229940107700 pyruvic acid Drugs 0.000 description 7
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 238000004128 high performance liquid chromatography Methods 0.000 description 5
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 4
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 3
- 229910021529 ammonia Inorganic materials 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 229930182817 methionine Natural products 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 229940054269 sodium pyruvate Drugs 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 206010003211 Arteriosclerosis coronary artery Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 241001269238 Data Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010020365 Homocystinuria Diseases 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000003143 atherosclerotic effect Effects 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000000151 deposition Methods 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000007824 enzymatic assay Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000002875 fluorescence polarization Methods 0.000 description 1
- 235000021588 free fatty acids Nutrition 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 230000003516 hyperlipidaemic effect Effects 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- -1 lipid peroxide Chemical class 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000036632 reaction speed Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Landscapes
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Description
HPLC法测定值(μmol/L) | 实施例1测定值(μmol/L) |
4.50 | 4.52 |
6.05 | 6.11 |
7.41 | 7.35 |
8.83 | 8.75 |
10.01 | 10.14 |
11.23 | 11.17 |
12.88 | 12.74 |
13.49 | 13.56 |
14.91 | 14.83 |
16.45 | 16.61 |
18.12 | 18.19 |
21.24 | 21.36 |
23.08 | 22.94 |
24.57 | 24.51 |
26.33 | 26.41 |
28.01 | 28.14 |
29.31 | 29.42 |
30.45 | 30.52 |
31.74 | 31.68 |
32.67 | 32.74 |
35.32 | 35.29 |
38.19 | 38.16 |
39.47 | 39.58 |
41.33 | 41.37 |
42.80 | 42.78 |
44.15 | 44.23 |
46.72 | 46.74 |
47.61 | 47.63 |
48.02 | 48.13 |
49.55 | 49.61 |
Claims (6)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 201110340135 CN102393373B (zh) | 2011-10-22 | 2011-10-22 | 一种消除内源性胱硫醚干扰的血清同型半胱氨酸测定方法及试剂 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 201110340135 CN102393373B (zh) | 2011-10-22 | 2011-10-22 | 一种消除内源性胱硫醚干扰的血清同型半胱氨酸测定方法及试剂 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102393373A true CN102393373A (zh) | 2012-03-28 |
CN102393373B CN102393373B (zh) | 2013-05-08 |
Family
ID=45860733
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 201110340135 Expired - Fee Related CN102393373B (zh) | 2011-10-22 | 2011-10-22 | 一种消除内源性胱硫醚干扰的血清同型半胱氨酸测定方法及试剂 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN102393373B (zh) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104546849A (zh) * | 2013-10-09 | 2015-04-29 | 上海交通大学 | 一种喹啉酮类化合物作为hCBS酶抑制剂的应用 |
CN106053615A (zh) * | 2015-04-16 | 2016-10-26 | 林伯刚 | 人类眼部的生物标记及其方法 |
CN106970230A (zh) * | 2017-03-29 | 2017-07-21 | 广州市伊川生物科技有限公司 | 一种同型半胱氨酸测定试剂盒 |
CN110954581A (zh) * | 2019-12-19 | 2020-04-03 | 湖南海源医疗科技股份有限公司 | 一种快速检测同型半胱氨酸的电化学方法 |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105628926A (zh) * | 2014-11-06 | 2016-06-01 | 上海中信国健药业股份有限公司 | 一种重组人ii型肿瘤坏死因子受体-抗体融合蛋白浓度测定方法 |
-
2011
- 2011-10-22 CN CN 201110340135 patent/CN102393373B/zh not_active Expired - Fee Related
Non-Patent Citations (3)
Title |
---|
袁玉亮: "同型半胱氨酸临床意义及检测方法", 《医学检验与临床》 * |
谭功军,卿之驹: "同型半胱氨酸检测技术的研究进展及评价", 《实用预防医学》 * |
陈咸川,李佳: "颈动脉硬化瘀证与血清同型半胱氨酸的关系探讨", 《辽宁中医药大学学报》 * |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104546849A (zh) * | 2013-10-09 | 2015-04-29 | 上海交通大学 | 一种喹啉酮类化合物作为hCBS酶抑制剂的应用 |
CN106053615A (zh) * | 2015-04-16 | 2016-10-26 | 林伯刚 | 人类眼部的生物标记及其方法 |
CN106970230A (zh) * | 2017-03-29 | 2017-07-21 | 广州市伊川生物科技有限公司 | 一种同型半胱氨酸测定试剂盒 |
CN106970230B (zh) * | 2017-03-29 | 2019-06-11 | 广州市伊川生物科技有限公司 | 一种同型半胱氨酸测定试剂盒 |
CN110954581A (zh) * | 2019-12-19 | 2020-04-03 | 湖南海源医疗科技股份有限公司 | 一种快速检测同型半胱氨酸的电化学方法 |
Also Published As
Publication number | Publication date |
---|---|
CN102393373B (zh) | 2013-05-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102393373B (zh) | 一种消除内源性胱硫醚干扰的血清同型半胱氨酸测定方法及试剂 | |
CN102435749A (zh) | 用循环酶法测定β-羟丁酸的液体稳定试剂盒 | |
CN101750327A (zh) | 氨基酸诊断/测定试剂(盒)及氨基酸的浓度测定方法 | |
Gómez et al. | Quantitative metabolic profiling of urinary eicosanoids for clinical phenotyping | |
CN103207175A (zh) | 一种游离脂肪酸测定试剂盒 | |
CN101639446A (zh) | 一种用化学发光法体外检测血液乳酸的方法 | |
Zhao et al. | Determination of pyruvic acid by using enzymic fluorescence capillary analysis | |
CN103602718A (zh) | 血清中甘油三酯的甘油脱氢酶测定方法 | |
CN101750354A (zh) | 腺苷脱氨酶诊断试剂(盒)及腺苷脱氨酶活性浓度测定方法 | |
CN101329336A (zh) | 甘油诊断/测定试剂盒及甘油的浓度测定方法 | |
CN101082573A (zh) | 果糖浓度的测定方法及果糖诊断试剂盒 | |
CN101750355A (zh) | 腺苷脱氨酶诊断试剂(盒)及腺苷脱氨酶活性浓度测定方法 | |
CN101750382A (zh) | 腺苷脱氨酶诊断试剂(盒)及腺苷脱氨酶活性浓度测定方法 | |
CN101750333A (zh) | 氨基酸诊断/测定试剂(盒)及氨基酸的浓度测定方法 | |
CN101762492A (zh) | 氨基酸诊断/测定试剂盒及氨基酸浓度测定方法 | |
CN101750357A (zh) | 氨基酸诊断/测定试剂(盒)及氨基酸的浓度测定方法 | |
JP2011177158A (ja) | タウリンの分析方法 | |
MacFarlane | Chemiluminescence and the Challenge to Attomole Detection | |
CN101750366A (zh) | 氨基酸诊断/测定试剂(盒)及氨基酸浓度测定方法 | |
CN101609011A (zh) | 腺苷脱氨酶诊断试剂盒及腺苷脱氨酶活性浓度测定方法 | |
CN101762488A (zh) | 氨基酸诊断/测定试剂(盒)及氨基酸的浓度测定方法 | |
CN101750286A (zh) | 氨基酸诊断/测定试剂(盒)及氨基酸的浓度测定方法 | |
CN101750367A (zh) | 氨基酸诊断/测定试剂(盒)及氨基酸的浓度测定方法 | |
CN101609010A (zh) | 腺苷脱氨酶诊断试剂盒及腺苷脱氨酶活性浓度测定方法 | |
CN101609009A (zh) | 腺苷脱氨酶诊断试剂盒及腺苷脱氨酶活性浓度测定方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: WENZHOU KANGYE MEDICAL TECHNOLOGY CO., LTD. Free format text: FORMER OWNER: WENZHOU DEFUTAI BIO-TECHNOLOGY CO., LTD. Effective date: 20140527 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 325025 WENZHOU, ZHEJIANG PROVINCE TO: 325000 WENZHOU, ZHEJIANG PROVINCE |
|
TR01 | Transfer of patent right |
Effective date of registration: 20140527 Address after: 325000 Zhejiang city of Wenzhou Province Jiao Feng Road No. 108 building 3 West first Patentee after: Wenzhou Kang Kang Medical Technology Co.,Ltd. Address before: Jiao Feng Road Lucheng District of Wenzhou City, Zhejiang Province, No. 108 325025 Patentee before: Wenzhou Defutai Bio-technology Co.,Ltd. |
|
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20130508 |